Just B with IXINITY®

It’s refreshing when a company really
connects with the community they’re providing treatment options for, which is
why today, I’m happy to spread the word about the new promotional campaign from
Aptevo, the makers of the factor IX treatment, IXINITY® [coagulation
factor IX (recombinant)]. 
 
Read below to get the story on how
people in the hemophilia B community inspired the campaign, plus see it for yourself at JustBIXperiences.com.


This is a paid public announcement from Aptevo and does not constitute an endorsement of products or services. When you click on the links in this blog entry, you will be directed to the IXINITY website. LA Kelley Communications always advises you to be a savvy consumer when contacting any company; do not reveal
identifying information against your will. 
 
 

Finding inspiration from familiar faces

As IXINITY marks its second anniversary
as a treatment option for those with hemophilia B, the people behind the
product are excited to start the next phase with a fresh new face. They didn’t
have to look very far, because who better to represent the close-knit
hemophilia B community and the company that cares about them than real people actually
using IXINITY? 

Introducing…

Just B: Because life is bigger than hemophilia
B, make it your IXperience™ with IXINITY.

Please see Important Safety Information for IXINITY below.

An idea that became an identity, inspired
by everyone who is redefining what it means to have hemophilia B by living life
on your own terms and Just B-ing yourself.
 
By sharing your experiences, your
expectations, and your aspirations, you’ve shown that, regardless of having
hemophilia or not, everyone deserves the chance to Just B.

Meet the first people to be featured
sharing their IXINITY stories (and see if there are any familiar faces from the
community that you recognize) at JustBIXperiences.com.

Plus, find out more about what it means
to Just B and get connected in the IXINITY Family Room on Facebook.

IXINITY INDICATIONS AND IMPORTANT SAFETY INFORMATION

What
is IXINITY®?
IXINITY [coagulation factor IX (recombinant)] is a medicine
used to replace clotting factor (factor IX) that is missing in adults and
children at least 12 years of age with hemophilia B. Hemophilia B is also
called congenital factor IX deficiency or Christmas disease. Hemophilia B is an
inherited bleeding disorder that prevents clotting. Your healthcare provider
may give you IXINITY to control and prevent bleeding episodes or when you have
surgery.
IXINITY is not indicated for induction of immune tolerance
in patients with hemophilia B.
IMPORTANT
SAFETY INFORMATION for IXINITY®

  • You
    should not use IXINITY if you are allergic to hamsters or any ingredients in IXINITY.
  • You
    should tell your healthcare provider if you have or have had medical problems,
    take any medicines, including prescription and non-prescription medicines, such
    as over-the-counter medicines, supplements, or herbal remedies, have any
    allergies, including allergies to hamsters, are nursing, are pregnant or
    planning to become pregnant, or have been told that you have inhibitors to
    factor IX.
  • You
    can experience an allergic reaction to IXINITY. Contact your healthcare
    provider or get emergency treatment right away if you develop a rash or hives,
    itching, tightness of the throat, chest pain, or tightness, difficulty
    breathing, lightheadedness, dizziness, nausea, or fainting.
  • Your
    body may form inhibitors to IXINITY. An inhibitor is part of the body’s defense
    system. If you develop inhibitors, it may prevent IXINITY from working
    properly. Consult with your healthcare provider to make sure you are carefully
    monitored with blood tests for development of inhibitors to IXINITY.
  • If
    you have risk factors for developing blood clots, the use of IXINITY may
    increase the risk of abnormal blood clots.
  • Call
    your healthcare provider right away about any side effects that bother you or
    do not go away, or if your bleeding does not stop after taking IXINITY.
  • The
    most common side effect that was reported with IXINITY during clinical trials
    was headache.
  • These
    are not all the side effects possible with IXINITY. You can ask your healthcare
    provider for information that is written for healthcare professionals.
For more information about IXINITY, please see full Prescribing Information,
including Important Patient Information.
 
You are encouraged to report side effects of prescription drugs to the
Food and Drug Administration. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Aptevo
BioTherapeutics LLC, Berwyn, PA 19312
IXINITY [coagulation factor IX
(recombinant)] and
any and all Aptevo
BioTherapeutics LLC brand, product, service and
feature names, logos, and slogans are trademarks or registered trademarks of Aptevo
BioTherapeutics LLC in the United States and/or
other countries.
©
2017 Aptevo BioTherapeutics. All rights reserved. CM-FIX-0159

Name Game, Game Change?

I’m thinking “game” this weekend because the Patriots are in the Super Bowl, again, and I will need to watch it like the rest of Boston. I only watched my first football game two years ago when, surprise surprise, the Patriots were in the Super Bowl. Every sports fan knows the Patriots, I am told. It’s easy to cheer for your home teams when the names (Red Sox, Patriots, Bruins, Celtics) endure for decades. It’s harder when it’s the drug companies that make your factor concentrate. There’s a lot of game changing going on lately.

The news was announced just three days ago: Biogen, maker of Eloctate and Alprolix, has spun off its hemophilia division, which has now become an entirely separate and new company called Bioverativ.

Biogen’s two revolutionary products, the first ones with a longer half-life, were game changers. Now there are a few more choices for longer half-life products, but these were the first and were rolled out with much fanfare. Then boom! Three years later, Biogen doesn’t want them anymore.

This is just a reminder to us patients that this is a marketplace, and we are consumers. And companies need to make business decisions—hence the “game.” As consumers, it’s up to us to understand how the game is played, and who are the players. The names have been changing, more rapidly than I can keep up with in the specialty pharmacy arena, and those are truly game changers.

In the factor concentrate manufacturing arena, we had two name changes just in the last few months: Biogen to Bioverativ, and Baxalta to Shire. But this has been happening for years in our community, so here’s a review. It’s worth knowing the players—of which YOU, the consumer, are the most important!

Remember Alpha? Those of you who use Alphanate or Alphanine may wonder why these drugs are called that when sold by the Spanish company Grifols. Simple: Grifols bought Alpha Therapeutics hemophilia therapies years ago and simply kept the drugs’ names the same. (It’s hard to change a drug’s name.) In 2011, Grifols also bought Talecris, making it the third-largest global manufacturer of plasma-derived therapies. Oh, and Talecris? It was a spin-off from Bayer, which didn’t want to keep plasma-therapies anymore. Bayer’s plasma-product Koate-DVI went to Talecris, and Bayer kept Kogenate FS. If you look at the Koate-DVI packaging, you’ll still see the Bayer primary color line around the box!

Baxter Healthcare produced factor concentrates like Recombinate, Advate, Hemofil M and FEIBA. It spun off its hemophilia division, which became an independent company called Baxalta. That didn’t last long. Shire, an Irish pharmaceutical company, liked what it saw and scooped it up. All the former Baxter/Baxalta products now belong to Shire.

The biggest name changer is CSL Behring. I knew it in 1987 as Armour Pharmaceutical. Then in 1996, Armour and Behringwerke (a Geman company) formed a joint venture known as Centeon. Things happen fast: in 1999, Centeon became Aventis Behring. Why? Armour’s parent companies (Rhone-Polenc Rorer and Hoechst) merged to become Aventis. Meanwhile, CSL (an Australian plasma therapies manufacturer) acquired ZLB Blood Transfusion Services. In 2004, CSL acquired Aventis Behring, to form ZLB Behring, later called CSL Behring.

(There’s a comprehensive timeline of this interesting company here.)

Genetics Institute: anyone remember that? They developed BeneFIX and ReFacto (no longer on the market). It evolved into Wyeth, and then was bought by pharma giant Pfizer Inc.

Bayer is one that seems to have stayed the same, but it’s had name changes too. Bayer bought Cutter Labs in 1978 and Miles Labs in 1979. In 1995, they all became Bayer. I think Novo Nordisk (Denmark) has stayed the same… so far!
And some companies dropped out altogether, like the American Red Cross.  And new ones entered, like Octapharma (Switzerland) and Kedrion (Italy), tapped to distribute Koate DVI for Grifols. And Aptevo Therapeutics… oh, which was owned by Cangene (Canada) first, then Cangene was bought by Emergent Biosolutions in 2014! And they all originated from Inspirational Biopharmaceuticals, which in 2013 sold all its product rights to them, and dropped out of the game.

More passes than Tom Brady!

Whew! It’s amazing tracking the history of just the name changes: but we also need to know products. We are tracking who makes what on our website Hemophilia Factor Chart by Brand, available as a download. We are updating it all the time… a necessity to keep track of this ever-changing game, and business.

See how James found the factor IX option he’d been searching for

As we’re full swing into the holiday spirit and a new year is just around the corner, it seems like the perfect time to

share this inspiring story of a young man with hemophilia B named James. Please read below to learn about his

story and his choice of treatment.

Laurie
After missing out on much of his life because of bleeds, James found a fresh start with the help of the right treatment for him…IXINITY® [coagulation factor IX (recombinant)].

Watch James share his story at IXINITY.com.

Interested in learning more about IXINITY? Connect with a Hemophilia Territory Manager near you at MyIXINITYRep.com.

And remember, this is James’ experience; different people may have different results. You should always talk to your doctor to decide which treatment is right for you.

Meet James

“Since birth I’ve used different hemophilia B products, and regardless of treatment, I continued to have breakthrough bleeds most every other week. I felt I had no control over my health, and that led me down a bad path as I started making some unhealthy choices in my teen years.

When I was 21, I saw an ad for a clinical trial of a new recombinant hemophilia B treatment. I thought, ‘I have nothing to lose.’

After a few weeks in the clinical trial, I stopped having bleeds almost entirely. I realized I didn’t know what feeling good felt like. I felt more in control, and it was a liberating experience.

One day I decided to go running—I don’t know what made me decide to because I’d never really done it before. But I thought, ‘I’m just going to go for a run,’ and about a mile later, I thought, ‘Huh! This is awesome’

After talking with my doctor, I’ve now developed a habit of running 3 times each week with my dog, and exercising regularly.
To be honest, switching to IXINITY was the best decision I ever made. I don’t feel like someone with hemophilia; I forget I even have it.”

See more of James’ journey at IXINITY.com.

James’ experience with IXINITY may not be typical. Speak with your doctor to see if IXINITY is the right treatment for you.

The content of this post is provided and sponsored by Aptevo Therapeutics.

IXINITY INDICATIONS AND IMPORTANT SAFETY INFORMATION

What is IXINITY®? 

IXINITY [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Hemophilia B is an inherited bleeding disorder that prevents clotting. Your healthcare provider may give you IXINITY to control and prevent bleeding episodes or when you have surgery.

IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

IMPORTANT SAFETY INFORMATION for IXINITY®

• You should not use IXINITY if you are allergic to hamsters or any ingredients in IXINITY.
• You should tell your healthcare provider if you have or have had medical problems, take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies, have any allergies, including allergies to hamsters, are nursing, are pregnant or planning to become pregnant, or have been told that you have inhibitors to factor IX.
• You can experience an allergic reaction to IXINITY. Contact your healthcare provider or get emergency treatment right away if you develop a rash or hives, itching, tightness of the throat, chest pain, or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or fainting.
• Your body may form inhibitors to IXINITY. An inhibitor is part of the body’s defense system. If you develop inhibitors, it may prevent IXINITY from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for development of inhibitors to IXINITY.
• If you have risk factors for developing blood clots, the use of IXINITY may increase the risk of abnormal blood clots.
• Call your healthcare provider right away about any side effects that bother you or do not go away, or if your bleeding does not stop after taking IXINITY.
• The most common side effect that was reported with IXINITY during clinical trials was headache.
• These are not all the side effects possible with IXINITY. You can ask your healthcare provider for information that is written for healthcare professionals.

For more information about IXINITY, please see full Prescribing Information, including Important Patient Information.

You are encouraged to report side effects of prescription drugs to the Food and Drug Administration. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Aptevo BioTherapeutics LLC, Berwyn, PA 19312

IXINITY [coagulation factor IX (recombinant)] and any and all Aptevo BioTherapeutics LLC brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Aptevo BioTherapeutics LLC in the United States and/or other countries.

© 2016 Aptevo Biotherapeutics. All rights reserved. CM-FIX-0093

IXINITY® is now brought to you by Aptevo Therapeutics

This
week, I’m excited to tell you about a new company made of up familiar faces within
the hemophilia B community. The people from Emergent who brought you IXINITY [coagulation
factor IX (recombinant)] are now continuing their tradition of being a different kind of company at Aptevo
Therapeutics.    

Continue reading for more
information about how Aptevo is still committed to putting people with
hemophilia B first.
Introducing
Aptevo Therapeutics
Aptevo
Therapeutics is a new biotech company focused on improving the lives of people
with bleeding disorders and cancer by combining extensive experience with the
drive to advance the science of what’s next.
By
connecting with people across the country to learn about their needs and continuing
to support community outreach programs that enrich peoples’ lives, our primary goal
is to provide high-quality, specialized therapies for people with rare
conditions.
When
it comes to the hemophilia B community, the same people from Emergent who pride
themselves on working for a different kind of company are now part of Aptevo.
So
while you may see a new business card, IXINITY is still the same, and you’ll
still connect with the same people you’ve come to trust.
Visit IXINITY.com to find out more about this
factor IX and the company behind it.

The content of
this post is provided and sponsored by Aptevo Therapeutics.


IXINITY INDICATIONS
AND IMPORTANT SAFETY INFORMATION
What is IXINITY®?

IXINITY [coagulation factor IX (recombinant)] is a medicine used to
replace clotting factor (factor IX) that is missing in adults and children at
least 12 years of age with hemophilia B.

Hemophilia B
is also called congenital factor IX deficiency or Christmas disease. Hemophilia
B is an inherited bleeding disorder that prevents clotting. Your healthcare
provider may give you IXINITY to control and prevent bleeding episodes or when
you have surgery.
IXINITY is
not indicated for induction of immune tolerance in patients with hemophilia B.
IMPORTANT SAFETY INFORMATION for IXINITY®
·    
You should not use IXINITY if you are
allergic to hamsters or any ingredients in IXINITY.
·    
You should tell your healthcare provider if
you have or have had medical problems, take any medicines, including
prescription and non-prescription medicines, such as over-the-counter
medicines, supplements, or herbal remedies, have any allergies, including
allergies to hamsters, are nursing, are pregnant or planning to become
pregnant, or have been told that you have inhibitors to factor IX.
·    
You can experience an allergic reaction to
IXINITY. Contact your healthcare provider or get emergency treatment right away
if you develop a rash or hives, itching, tightness of the throat, chest pain,
or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or
fainting.
·    
Your body may form inhibitors to IXINITY. An
inhibitor is part of the body’s defense system. If you develop inhibitors, it
may prevent IXINITY from working properly. Consult with your healthcare
provider to make sure you are carefully monitored with blood tests for
development of inhibitors to IXINITY.
·    
If you have risk factors for developing blood
clots, the use of IXINITY may increase the risk of abnormal blood clots.
·    
Call your healthcare provider right away
about any side effects that bother you or do not go away, or if your bleeding
does not stop after taking IXINITY.
·    
The most common side effect that was reported with IXINITY during
clinical trials was headache.
·     These are
not all the side effects possible with IXINITY. You can ask your healthcare
provider for information that is written for healthcare professionals.
Please see full Prescribing Information
You are encouraged to report side effects of prescription drugs to the
Food and Drug Administration. Visit the
www.fda.gov/medwatch, or call
1-800-FDA-1088.
 
Aptevo BioTherapeutics LLC, Berwyn, PA
19312

IXINITY [coagulation factor IX (recombinant)] and any and all Aptevo BioTherapeutics LLC brand, product, service and feature names, logos, and
slogans are trademarks or registered trademarks of Aptevo
BioTherapeutics LLC in the United States and/or
other countries.

© 2016 Aptevo Biotherapeutics. All rights reserved. CM-FIX-0070 

ADVERTISEMENT